What are the Mechanisms of HIV Latency and Persistence? The government has an extensive plan for conducting AIDS research, but finding a cure is not part of it. By Bob Huff Two of the great quests in science are to…
Recommendations submitted by Treatment Action Group to President Barack Obama on ways to strengthen the struggle to end AIDS Demonstrate Strong Domestic and Global Leadership TAG urges President Obama to make fighting AIDS a national and global priority through…
Life and Work of an AIDS Activist The world lost one of the pioneers of AIDS activism when Project Inform founder Martin Delaney died of liver cancer in San Rafael, California. By Mark Harrington Fighting for people with HIV until…
The Union Conference provides an important opportunity for TAG to exert its activist influence on all of the key people in the fight against TB. By Javid Syed The tuberculosis universe convenes once a year at the World Conference on…
By Bob Huff A speculative history of HIV treatment presented at the PATH aids2031 meeting “Discovery and Innovation for HIV/AIDS ” held in Seattle, November 18, 2008. 1981 First reports of disease later known as AIDS; 100 percent fatality feared…
International Advocacy Update By Claire Wingfield TPresentations from TAG’s recent meeting on universal access to TB and HIV treatment, care, and prevention as well as TAG ’s Funding Trends in TB R&D 2005–2007: A Preliminary Report, are available online. The…
Just Another Initiative? By Sue Perez Despite the constant uphill battle in getting its issues on the table and our concerns heard, civil society recognizes that the International Health Partnership presents opportunities. Launched in September 2007 by UK Prime Minister…
Making Treatment Decisions in an Evidence-Free Zone By Lei Chou New drug development; treatment strategies; natural history; long-term outcomes: The lack of support for research on hepatitis B virus is putting millions of people with the virus at risk. People…
New Studies of Microbial Translocation By Richard Jefferys Immune activation has become a central culprit in the latest theories of how HIV causes disease. But despite increasing research on the question, the sources of immune activation continue to puzzle scientists…
Questions Linger on Initiating and Switching HIV Treatment When and how to start antiretroviral therapy—and how to respond down the line when changes become necessary—remain unsettled questions. Amid a plethora of therapeutic options, gaps remain in our understanding about when…